Q-omics provides the consensus-scored GAPDHP37 profile across patient tissues and cancer cell-line models. GAPDHP37 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, GAPDHP37 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, GAPDHP37 RNA expression shows 10,488 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, KIRC, and THYM as cancer lineages where GAPDHP37 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP37 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP37 survival associations across molecular data types. GAPDHP37 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP37 RNA expression–survival associations across cancer types. High GAPDHP37 expression shows unfavorable associations in KICH, MESO, DLBC and UVM, but favorable associations in BRCA and UCEC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for GAPDHP37 RNA expression.
This table summarizes GAPDHP37 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP37. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP37 shows lower tumor expression in CHOL and higher tumor expression in KIRC, COAD, LIHC and PAAD. The KIRC box plot shows higher GAPDHP37 RNA expression in tumor versus normal tissue (log2 FC = +0.132, t-test p < 0.001).
This table shows molecular features associated with GAPDHP37 in patient tissues and cancer cell lines. In patient samples, GAPDHP37 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
